Mid-dose losartan mitigates diabetes-induced hepatic damage by regulating iNOS, eNOS, VEGF, and NF-kappa B expressions


Oltulu F. , Buhur A., Gürel Ç., Kuşçu G., Dağdeviren M., Karabay Y. , ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, ss.1582-1589, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 49 Konu: 5
  • Basım Tarihi: 2019
  • Doi Numarası: 10.3906/sag-1901-15
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Sayfa Sayıları: ss.1582-1589

Özet

Background/aim: Losartan, an antihypertensive drug, is highly preferred in patients with diabetes mellitus (DM) and hypertension because of its retarding effect on diabetic nephropathy. In this study, we investigated the potential therapeutic effect of different doses of losartan on hepatic damage in a streptozotocin (STZ, 50 mg/kg)-induced DM model in rats.